Capsid-modified rAAV vector compositions and methods therefor
Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.
1. A modified AAV capsid protein, comprising:
(A) a non-serine amino acid residue at a position corresponding to S663 of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6 and
(B) a non-threonine amino acid residue at a position corresponding to T492 of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6.
2. The modified AAV capsid protein of claim 1 , further comprising: (i) a non-tyrosine amino acid residue at one or more positions corresponding to Y445, Y705 and Y731 of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6; or (ii) one or more positions corresponding to Y444, Y500 and Y730 of the wild-type AAV2 capsid protein as set forth in SEQ ID NO:2.
3. The modified AAV capsid protein of claim 2 , wherein
(a) the non-tyrosine or non-threonine amino acid residue is selected from the group consisting of serine (S), phenylalanine (F), valine (V), histidine (H), isoleucine (I), alanine (A), leucine (L) aspartic acid (D), asparagine (N), glutamic acid (E), arginine (R), and isoleucine (I); or
(b) the non-serine amino acid residue is selected from the group consisting of phenylalanine (F), valine (V), histidine (H), isoleucine (I), alanine (A), leucine (L) aspartic acid (D), asparagine (N), glutamic acid (E), arginine (R), and isoleucine (I).
4. The modified AAV capsid protein of claim 2 , wherein
(a) the non-tyrosine amino acid residue at one or more positions corresponding to Y445, Y705 and Y731 of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6 or
(b) the non-tyrosine amino acid residue at one or more positions corresponding to Y444, Y500 and Y730 of the wild-type AAV2 capsid protein as set forth in SEQ ID NO:2, is phenyalanine.
5. The modified AAV capsid protein of claim 1 , wherein the non-serine amino acid residue at a position corresponding to S663 of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6 is valine.
6. The modified AAV capsid protein of claim 1 , wherein the non-threonine amino acid residue at a position corresponding to T492 of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6 is valine.
7. A composition comprising:
(I)
(a) the modified AAV capsid protein of claim 1 ;
(b) a nucleic acid segment that encodes the modified AAV capsid protein of claim 1 ; or
(c) a viral particle comprising the modified AAV capsid protein of claim 1 ; and
(II) a pharmaceutically-acceptable buffer, diluent, or excipient.
8. The modified AAV capsid protein of claim 1 , wherein the modified AAV capsid protein has a sequence of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6 further comprising a Valine at the position corresponding to S663 and a Valine at the position corresponding to T492.
9. The modified AAV capsid protein of claim 1 , wherein the modified AAV capsid protein is a modified AAV1, AAV3, AAV4, AAV5, AAV7, AAV9, or AAV10 capsid protein.
10. The modified AAV capsid protein of claim 1 , wherein the modified AAV capsid protein is a VP1 capsid protein.
11. The modified AAV capsid protein of claim 1 , wherein the modified AAV capsid protein is a VP2 capsid protein.
12. The modified AAV capsid protein of claim 1 , wherein the modified AAV capsid protein is a VP3 capsid protein.
13. An rAAV viral particle comprising the modified AAV capsid protein of claim 1 .
14. The rAAV viral particle of claim 13 , wherein the rAAV viral particle further comprises a recombinant polynucleotide that encodes a gene of interest.